|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lahiri A, Maji A, Potdar PD, Singh N,
Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer
immunotherapy: Progress, pitfalls, and promises. Mol Cancer.
22(40)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mamdani H, Matosevic S, Khalid AB, Durm G
and Jalal SI: Immunotherapy in lung cancer: Current landscape and
future directions. Front Immunol. 13(823618)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mino-Kenudson M, Schalper K, Cooper W,
Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y,
Beasley MB, et al: Predictive biomarkers for immunotherapy in lung
cancer: Perspective from the international association for the
study of lung cancer pathology committee. J Thorac Oncol.
17:1335–1354. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nagy S, Demory Beckler M, Hussein A and
Kesselman MM: The development of diabetes and diabetic ketoacidosis
following immunotherapy treatment: A systematic review of case
reports. Cureus. 16(e57894)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Berraondo P, Sanmamed MF, Ochoa MC,
Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME,
Ponz-Sarvise M, Castañón E and Melero I: Cytokines in clinical
cancer immunotherapy. Br J Cancer. 120:6–15. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chaplin DD: Overview of the immune
response. J Allergy Clin Immunol. 125 (2 Suppl 2):S3–S23.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lan T, Chen L and Wei X: Inflammatory
cytokines in cancer: Comprehensive understanding and clinical
progress in gene therapy. Cells. 10(100)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jorgovanovic D, Song M, Wang L and Zhang
Y: Roles of IFN-γ in tumor progression and regression: A review.
Biomark Res. 8(49)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Alspach E, Lussier DM and Schreiber RD:
Interferon γ and its important roles in promoting and inhibiting
spontaneous and therapeutic cancer immunity. Cold Spring Harb
Perspect Biol. 11(a028480)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
PDQ Supportive and Palliative Care
Editorial Board: Family Caregivers in Cancer: Roles and Challenges
(PDQ®). In: PDQ Cancer Information Summaries. National Cancer
Institute, Bethesda, 2010.
|
|
14
|
Chae YK, Chiec L, Mohindra N, Gentzler R,
Patel J and Giles F: A case of pembrolizumab-induced type-1
diabetes mellitus and discussion of immune checkpoint
inhibitor-induced type 1 diabetes. Cancer Immunol Immunother.
66:25–32. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhao N, Yi Y, Cao W, Fu X, Mei N and Li C:
Serum cytokine levels for predicting immune-related adverse events
and the clinical response in lung cancer treated with
immunotherapy. Front Oncol. 12(923531)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang C, Mo H, Li M, Wang S, Dou X and
Zhang X: The effects of postoperative targeted immunotherapy on
peripheral blood cytokines and immune cell profile in lung cancer
patients. Front Oncol. 14(1342624)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sanmamed MF, Perez-Gracia JL, Schalper KA,
Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro
C, Martín-Algarra S, et al: Changes in serum interleukin-8 (IL-8)
levels reflect and predict response to anti-PD-1 treatment in
melanoma and non-small-cell lung cancer patients. Ann Oncol.
28:1988–1995. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Netterberg I, Li C, Molinero L, Budha N,
Sukumaran S, Stroh M, Jonsson EN and Friberg LE: A PK/PD analysis
of circulating biomarkers and their relationship to tumor response
in atezolizumab-treated non-small cell lung cancer patients. Clin
Pharmacol Ther. 105:486–495. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Janho Dit Hreich S, Hofman P and
Vouret-Craviari V: The role of IL-18 in P2RX7-mediated antitumor
immunity. Int J Mol Sci. 24(9235)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang Y, Chen H, Zhang T, Yang X, Zhong J,
Wang Y, Chi Y, Wu M, An T, Li J, et al: Plasma cytokines
interleukin-18 and CXC motif chemokine ligand 10 are indicative of
the anti-programmed cell death protein-1 treatment response in lung
cancer patients. Ann Transl Med. 9(33)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhou T, Damsky W, Weizman OE, McGeary MK,
Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, et
al: IL-18BP is a secreted immune checkpoint and barrier to IL-18
immunotherapy. Nature. 583:609–614. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Savid-Frontera C, Viano ME, Baez NS, Lidon
NL, Fontaine Q, Young HA, Vimeux L, Donnadieu E and Rodriguez-Galan
MC: Exploring the immunomodulatory role of virtual memory CD8+ T
cells: Role of IFN gamma in tumor growth control. Front Immunol.
13(971001)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen B, Yang M, Li K, Li J, Xu L, Xu F, Xu
Y, Ren D, Zhang J and Liu L: Immune-related genes and gene sets for
predicting the response to anti-programmed death 1 therapy in
patients with primary or metastatic non-small cell lung cancer.
Oncol Lett. 22(540)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Senju H, Kumagai A, Nakamura Y, Yamaguchi
H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura
H, et al: Effect of IL-18 on the expansion and phenotype of human
natural killer cells: Application to cancer immunotherapy. Int J
Biol Sci. 14:331–340. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Janho Dit Hreich S, Humbert O, Pacé-Loscos
T, Schiappa R, Juhel T, Ilié M, Ferrari V, Benzaquen J, Hofman P
and Vouret-Craviari V: Plasmatic inactive IL-18 predicts a worse
overall survival for advanced non-small-cell lung cancer with early
metabolic progression after immunotherapy initiation. Cancers
(Basel). 16(2226)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jiao J, Li WW, Shang YH, Li XF and Jiao M:
Clinical effects of Chemotherapy combined with Immunotherapy in
patients with advanced NSCLC and the effect on their nutritional
status and immune function. Pakistan J Med Sci. 39:404–408.
2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schoenfeld DA, Djureinovic D, Su DG, Zhang
L, Lu BY, Kamga L, Mann JE, Huck JD, Hurwitz M, Braun DA, et al:
Decoy-resistant IL-18 reshapes the tumor microenvironment and
enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI
insight. 10(e184545)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kessel C, Rossig C and Abken H: Weal and
woe of interleukin-18 in the T cell therapy of cancer. J Immunother
Cancer. 13(e010545)2025.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Orengo AM, Fabbi M, Miglietta L, Andreani
C, Bruzzone M, Puppo A, Cristoforoni P, Centurioni MG, Gualco M,
Salvi S, et al: Interleukin (IL)-18, a biomarker of human ovarian
carcinoma, is predominantly released as biologically inactive
precursor. Int J cancer. 129:1116–1125. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Parker BS, Rautela J and Hertzog PJ:
Antitumour actions of interferons: Implications for cancer therapy.
Nat Rev Cancer. 16:131–144. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang J, Song D, Dong Y, Bai L, Gao D,
Zhang S, Guo Y, Li F, Ao M and Li Q: Effects of Chemotherapy on
peripheral blood NK cell receptor NKG2D and related immune
cytokines in patients with non-small cell lung cancer. J Cancer
Ther. 13:631–639. 2022.
|
|
32
|
Feng X, Zhang Z, Sun P, Song G, Wang L,
Sun Z, Yuan N, Wang Q and Lun L: Interleukin-18 is a prognostic
marker and plays a tumor suppressive role in colon cancer. Dis
Markers. 2020(6439614)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Jiang K, Lin B, Zhang Y, Lu K, Wu F and
Luo D: A Novel Pyroptosis-Related Gene Signature for Prediction of
Disease-Free Survival in Papillary Thyroid Carcinoma. J Pers Med.
13(85)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nakanishi K: Unique action of
interleukin-18 on T cells and other immune cells. Front Immunol.
9(763)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X
and Li L: IFN-γ-mediated inhibition of lung cancer correlates with
PD-L1 expression and is regulated by PI3K-AKT signaling. Int J
Cancer. 143:931–943. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Burke JD and Young HA: IFN-γ: A cytokine
at the right time, is in the right place. Semin Immunol.
43(101280)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in Melanoma. N
Engl J Med. 375:819–829. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Song M, Ping Y, Zhang K, Yang L, Li F,
Zhang C, Cheng S, Yue D, Maimela NR, Qu J, et al: Low-dose IFNγ
induces tumor cell stemness in tumor microenvironment of non-small
cell lung cancer. Cancer Res. 79:3737–3748. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shin DS, Zaretsky JM, Escuin-Ordinas H,
Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W,
Sandoval S, Torrejon DY, et al: Primary resistance to PD-1 blockade
mediated by JAK1/2 mutations. Cancer Discov. 7:188–201.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Boutsikou E, Domvri K, Hardavella G,
Tsiouda D, Zarogoulidis K and Kontakiotis T: Tumour necrosis
factor, interferon-gamma and interleukins as predictive markers of
antiprogrammed cell-death protein-1 treatment in advanced non-small
cell lung cancer: A pragmatic approach in clinical practice. Ther
Adv Med Oncol. 10(1758835918768238)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guo Q, Wu CY, Jiang N, Tong S, Wan JH,
Xiao XY, Mei PY, Liu HS and Wang SH: Downregulation of T-cell
cytotoxic marker IL18R1 promotes cancer proliferation and migration
and is associated with dismal prognosis and immunity in lung
squamous cell carcinoma. Front Immunol. 13(986447)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Talab TJ, Shafi FAA and Jasim SM:
Association between immune-related adverse events and therapeutic
outcomes in patients with advanced non-small cell lung cancer
treated with pembrolizumab: A retrospective study. World Acad Sci
J. 7:1–9. 2025.
|
|
43
|
Bajwa R, Cheema A, Khan T, Amirpour A,
Paul A, Chaughtai S, Patel S, Patel T, Bramson J, Gupta V, et al:
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1
Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4
Inhibitors): Results of a Retrospective Study. J Clin Med Res.
11:225–236. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Casagrande S, Sopetto GB, Bertalot G,
Bortolotti R, Racanelli V, Caffo O, Giometto B, Berti A and Veccia
A: Immune-related adverse events due to cancer immunotherapy:
Immune mechanisms and clinical manifestations. Cancers (Basel).
16(1440)2024.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Grigorian A and O'Brien CB: Hepatotoxicity
secondary to chemotherapy. J Clin Transl Hepatol. 2:95–102.
2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
European Association for the Study of the
Liver. EASL clinical practice guidelines: Drug-induced liver
injury. J Hepatol. 70:1222–1261. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Clarke SJ, Abratt R, Goedhals L, Boyer MJ,
Millward MJ and Ackland SP: Phase II trial of pemetrexed disodium
(ALIMTA, LY231514) in chemotherapy-naïve patients with advanced
non-small-cell lung cancer. Ann Oncol. 13:737–741. 2002.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ohe Y, Ichinose Y, Nakagawa K, Tamura T,
Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y,
et al: Efficacy and safety of two doses of pemetrexed supplemented
with folic acid and vitamin B12 in previously treated patients with
non-small cell lung cancer. Clin Cancer Res. 14:4206–4212.
2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Smit EF, Mattson K, Von Pawel J, Manegold
C, Clarke S and Postmus PE: ALIMTA (pemetrexed disodium) as
second-line treatment ofnon-small-cell lung cancer: A phase II
study. Ann Oncol. 14:455–460. 2003.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sakamori Y, Kim YH, Yoshida H, Nakaoku T,
Nagai H, Yagi Y, Ozasa H and Mishima M: Effect of liver toxicity on
clinical outcome of patients with non-small-cell lung cancer
treated with pemetrexed. Mol Clin Oncol. 3:334–340. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mohammed Bakheet M, Mohssin Ali H and
Jalil Talab T: Evaluation of some proinflammatory cytokines and
biochemical parameters in pre and postmenopausal breast cancer
women. Cytokine. 179(156632)2024.PubMed/NCBI View Article : Google Scholar
|
|
52
|
King PD and Perry MC: Hepatotoxicity of
chemotherapy. Oncologist. 6:162–176. 2001.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Guo X, Li W, Hu J, Zhu EC and Su Q:
Hepatotoxicity in patients with solid tumors treated with
PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus
chemotherapy, or chemotherapy alone: Systematic review and
meta-analysis. Eur J Clin Pharmacol. 76:1345–1354. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Larroquette CA, Hortobagyi GN, Buzdar AU
and Holmes FA: Subclinical hepatic toxicity during combination
chemotherapy for breast cancer. JAMA. 256:2988–2990.
1986.PubMed/NCBI
|
|
55
|
Huffman BM, Kottschade LA, Kamath PS and
Markovic SN: Hepatotoxicity after immune checkpoint inhibitor
therapy in Melanoma: Natural progression and management. Am J Clin
Oncol. 41:760–765. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kwok G, Yau TC, Chiu JW, Tse E and Kwong
YL: Pembrolizumab (keytruda). Hum Vaccin Immunother. 12:2777–2789.
2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
De Martin E, Michot JM, Papouin B,
Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A,
Laghouati S, et al: Characterization of liver injury induced by
cancer immunotherapy using immune checkpoint inhibitors. J Hepatol.
68:1181–1190. 2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zhao P, Yu L, Ma W and Zhao T: Clinical
Manifestations and Risk Factors of Liver Injury Induced by PD-1
Inhibitors in Patients with Malignancies: A Case-Control Study.
Ther Clin Risk Manag. 21:309–320. 2025.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Tamaki N, Mori N, Takaki S, Tsuji K, Tada
T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, et al:
Change in liver function in durvalumab plus tremelimumab treatment
for unresectable hepatocellular carcinoma. Anticancer Res.
44:3913–3918. 2024.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Izzedine H, Mathian A, Champiat S, Picard
C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, et
al: Renal toxicities associated with pembrolizumab. Clin Kidney J.
12:81–88. 2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Xipell M, Victoria I, Hoffmann V,
Villarreal J, Garcia-Herrera A, Reig O, Rodas L, Blasco M, Poch E,
Mellado B and Quintana LF: Acute tubulointerstitial nephritis
associated with atezolizumab, an anti-programmed death-ligand 1
(pd-l1) antibody therapy. Oncoimmunology.
7(e1445952)2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Esfahani K, Meti N, Miller WH Jr and
Hudson M: Adverse events associated with immune checkpoint
inhibitor treatment for cancer. CMAJ. 191:E40–E46. 2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Espi M, Teuma C, Novel-Catin E, Maillet D,
Souquet PJ, Dalle S, Koppe L and Fouque D: Renal adverse effects of
immune checkpoints inhibitors in clinical practice: ImmuNoTox
study. Eur J Cancer. 147:29–39. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Rassy EE, Kourie HR, Rizkallah J, Karak
FE, Hanna C, Chelala DN and Ghosn M: Immune checkpoint inhibitors
renal side effects and management. Immunotherapy. 8:1417–1425.
2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Borówka M, Łącki-Zynzeling S, Nicze M,
Kozak S and Chudek J: Adverse renal effects of anticancer
immunotherapy: A review. Cancers (Basel). 14(4086)2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Sury K, Perazella MA and Shirali AC:
Cardiorenal complications of immune checkpoint inhibitors. Nat Rev
Nephrol. 14:571–588. 2018.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Waeckerle-Men Y, Starke A and Wüthrich RP:
PD-L1 partially protects renal tubular epithelial cells from the
attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant.
22:1527–1536. 2007.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Murakami N, Borges TJ, Yamashita M and
Riella LV: Severe acute interstitial nephritis after combination
immune-checkpoint inhibitor therapy for metastatic melanoma. Clin
Kidney J. 9:411–417. 2016.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J and Jordan K: ESMO Guidelines Committee.
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28
(suppl 4):iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
Society of Clinical Oncology Clinical Practice Guideline. J Clin
Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hughes J, Vudattu N, Sznol M, Gettinger S,
Kluger H, Lupsa B and Herold KC: Precipitation of autoimmune
diabetes with anti-PD-1 immunotherapy. Diabetes Care. 38:e55–e57.
2015.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Hansen E, Sahasrabudhe D and Sievert L: A
case report of insulin-dependent diabetes as immune-related
toxicity of pembrolizumab: Presentation, management and outcome.
Cancer Immunol Immunother. 65:765–767. 2016.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Carrero JA, McCarthy DP, Ferris ST, Wan X,
Hu H, Zinselmeyer BH, Vomund AN and Unanue ER: Resident macrophages
of pancreatic islets have a seminal role in the initiation of
autoimmune diabetes of NOD mice. Proc Natl Acad Sci USA.
114:E10418–E10427. 2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Schnell PM, Kassem M, Miah A, Ramaswamy B,
Williams N, Cherian M, Stover DG, Gatti-Mays ME, Pariser A,
Wesolowski R, et al: Changes in glucose level during chemotherapy
treatment in patients with stage I-IV breast cancer. Clin Breast
Cancer: May 27, 2025 (Epub ahead of print).
|
|
75
|
Fang TZ, Wu XQ, Zhao TQ, Wang SS, Fu GM,
Wu QL and Zhou CW: Influence of blood glucose fluctuations on
chemotherapy efficacy and safety in type 2 diabetes mellitus
patients complicated with lung carcinoma. World J Diabetes.
15:645–653. 2024.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau I, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Inzucchi SE and Lupsa B: Clinical
presentation, diagnosis, and initial evaluation of diabetes
mellitus in adults-UpToDate. https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-initial-evaluation-of-diabetes-mellitusin-adults.
2021.
|
